


45026.00096.UTL1
PATENT**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of the formula:




(I)

OR




(II)

OR

45026.00096.UTL1
PATENT


(III)

OR




(IV)

OR




(V)

OR




(VI)

OR

45026.00096.UTL1
PATENT

(VII)

OR



(VIII)

wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, NO_2 , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{13}$, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl and $\text{C}_1\text{-C}_8$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^2 is selected from the group of hydrogen, F, Cl, Br, I, CH_3 , CF_3 , CHF_2 , CH_2F , CF_2Cl , CN, $\text{CF}_2\text{OR}^{12}$, $\text{CH}_2\text{OR}^{12}$, OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{13}$, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkenyl and $\text{C}_2\text{-C}_8$ alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups may be optionally substituted;

R^3 through R^8 each independently is selected from the group of hydrogen, F, Cl, Br, I, OR^{12} , $\text{NR}^{12}\text{R}^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_2\text{-C}_8$ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups may be optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally substituted;

45026.00096.UTL1
PATENT

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, CN, OR^{12} , $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}C(O)R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups may be optionally substituted;

R^{11} is selected from the group of hydrogen, F, Br, Cl, I, CN, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, OR^{14} , $NR^{14}R^{13}$, and SR^{14} , CH_2R^{14} , $C(O)R^{14}$, CO_2R^{14} , $C(O)NR^{14}R^{13}$, SOR^{14} and SO_2R^{14} , wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^{12} and R^{13} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted;

R^{14} is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups may be optionally substituted;

R^{15} and R^{16} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

W is O or S;

X is selected from the group of O, S and N(R^{14});

Y is selected from the group of O, S, N(R^{12}), and NO(R^{12}) and $CR^{12}R^{13}$;

Z is selected from the group of O, S and N(R^{12});

n is 0, 1 or 2;

m is 0[,] or 1;

and/or a pharmaceutically acceptable salts thereof.

2. (Original) A compound according to claim 1, wherein R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

3. (Original) A compound according to claim 1, wherein R^2 is selected from the group of CF_2OR^{12} , CH_2OR^{12} , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} and $NR^{12}R^{13}$.

45026.00096.UTL1
PATENT

4. (Original) A compound according to claim 1, wherein R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 heteroalkyl, C_2-C_4 alkenyl and C_2-C_4 alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups may be optionally substituted.

5. (Original) A compound according to claim 4, wherein R^2 is selected from the group of hydrogen, F, Cl, CF_3 , CF_2Cl , CF_2H , CFH_2 and optionally substituted C_1-C_4 alkyl.

6. (Original) A compound according to claim 1, wherein R^9 and R^{10} each independently is selected from hydrogen, F, Cl, Br, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted

7. (Original) A compound according to claim 6, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

8. (Original) A compound according to claim 7, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F and CH_3 .

9. (Original) A compound according to claim 1, wherein R^1 is selected from the group of hydrogen, F, Cl, Br, I, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

10. (Original) A compound according to claim 9, wherein R^1 is selected from the group of hydrogen, F, Cl, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

11. (Original) A compound according to claim 9, wherein R^1 is hydrogen or F.

45026.00096.UTL1
PATENT

12. (Original) A compound according to claim 1, wherein Y and W each independently is O or S.
13. (Original) A compound according to claim 12, wherein Y and W are each O.
14. (Currently amended) A compound according to claim 1, wherein R¹¹ is selected from the group of ~~hydrogen~~, F, Br, Cl, CN, ~~C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl~~, OR¹⁴, NR¹⁴R¹³, and SR¹⁴, CH₂R¹⁴, C(O)R¹⁴, CO₂R¹⁴, C(O)NR¹⁴R¹³, SOR¹⁴ and SO₂R¹⁴, ~~wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.~~
15. (Currently amended) A compound according to claim 14, wherein R¹¹ is selected from the group of ~~hydrogen~~, F, Cl, OR¹⁴, SR¹⁴, and NR¹⁴R¹³, CH₂R¹⁴, C(O)R¹⁴, CO₂R¹⁴, C(O)NR¹⁴R¹³, SOR¹⁴, SO₂R¹⁴ and ~~optionally substituted C1-C4 alkyl.~~
16. (Currently amended) A compound according to claim 15, wherein R¹¹ is selected from the group of ~~hydrogen~~, F, Cl, OR¹⁴ and SR¹⁴.
17. (Original) A compound according to claim 16, wherein R¹¹ is OR¹⁴.
18. (Original) A compound according to claim 1, wherein Z is O or N{R¹²}.
19. (Original) A compound according to claim 18, wherein Z is N{R¹²}.
20. (Original) A compound according to claim 18, wherein Z is O.
21. (Original) A compound according to claim 1, wherein n is 0 or 1.
22. (Original) A compound according to claim 21, wherein n is 0.

45026.00096.UTL1
PATENT

23. (Original) A compound according to claim 1, wherein R^{12} is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted.

24. (Original) A compound according to claim 23, wherein R^{12} is selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

25. (Original) A compound according to claim 1, wherein R^{13} is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted.

26. (Original) A compound according to claim 25, wherein R^{13} is selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

27. (Original) A compound according to claim 1, wherein X is O or $N\{R^{14}\}$.

28. (Original) A compound according to claim 27, wherein X is $N\{R^{14}\}$.

29. (Original) A compound according to claim 28, wherein X is NH.

30. (Original) A compound according to claim 1, wherein R^3 and R^4 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^4 and R^6 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

45026.00096.UTL1
PATENT

31. (Original) A compound according to claim 30, wherein R^3 and R^4 each independently is selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

32. (Original) A compound according to claim 1, wherein R^5 and R^7 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R^5 and R^7 taken together form a bond.

33. (Original) A compound according to claim 32, wherein R^5 and R^7 each independently is selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

34. (Original) A compound according to claim 1, wherein R^6 and R^8 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups may be optionally substituted; or

R^6 and R^8 taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

35. (Original) A compound according to claim 34, wherein R^6 and R^8 each independently is selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 heteroalkyl, heteroaryl and aryl, wherein alkyl, haloalkyl, heteroaryl and aryl may be optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

36. (Original) A compound according to claim 1, wherein:

45026.00096.UTL1
PATENT

R^1 is selected from the group of hydrogen, F, Cl, Br, I, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^2 is selected from the group of hydrogen, F, Cl, Br, CF₃, CF₂Cl, CF₂H, CFH₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; and

R^3 and R^4 each independently is selected from the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

37. (Original) A compound according to claim 36, wherein:

R^5 through R^8 each independently is selected from the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

38. (Original) A compound according to claim 37, wherein:

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^{12} is selected from the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted; and

R^{14} is selected from the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C(O) R^{15} , CO₂ R^{15} and C(O)NR¹⁵ R^{16} , wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

39. (Currently amended) A compound according to claim 38, wherein[:]

~~W is O or S;~~

~~X is O or N(R¹⁴);~~

45026.00096.UTL1
PATENT

Y is O or S[:]

Z is O or N(R¹²); and

n is 0 or 1.

40. (Currently amended) A compound according to claim 1, wherein said compound is selected from the group of:

- ~~5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~5,6,7,8-Tetrahydro-7,7-diethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~7,8-Dihydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~5,6,7,8-Tetrahydro-7,7,8-trimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~8-Ethyl-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethyl-8-propylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~6-Hydrazino-4-trifluoromethylquinolin-2(1H)-one;~~
~~6-Methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~5-Isopropyl-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~5-Allyl-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~5-(4-Methoxyphenyl)-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~5-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~4-Trifluoromethyl-5,6,7,8-tetrahydrocyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~4-Trifluoromethyl-5,6,7,8,9,10-hexahydrocycloheptano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~(±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;~~
~~(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;~~

45026.00096.UTL1
PATENT

- (±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-ethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;
- (±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-7,8-Dihydro-7,8-*cis*-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(3-furanylmethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(3-thiophenemethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,8,8a(cis)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9H-cyclohexano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,8,9,9a(cis),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-trifluoromethylcycloheptano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-*cis*-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;

45026.00096.UTL1
PATENT

- (±)-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6- *cis*-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6- *cis*-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6- *cis*-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-(2-ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 6-Ethyl-5-methyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

45026.00096.UTL1
PATENT

5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
9-Trifluoroethyl-4-trifluoromethyl-9H-benzo[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[i]pyrrolo[2,3-g]quinolin-2(1H)-one;
5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(2-Ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;
5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinoline;
6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
7-Allyl-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;

45026.00096.UTL1
PATENT

6-Ethyl-7-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;
7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;
7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;
(+)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(-)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
4-Trifluoromethyl-6,7-dihydro-7,7,9-trimethyl-pyrido[2,3-g]quinolin-2(1H)-one;
8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-5,7,7-trimethylpyrido[3,2-f]quinolin-2(1H)-one;
4,5,7-Tri(trifluoromethyl)pyrido[3,2-f]quinolin-2(1H)-one;
5,7-Bis(trifluoromethyl)pyrido[3,2-f]quinolin-2(1H)-one;
4-Trifluoromethyl-7-methyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-7,8-dihydro-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-5,6,7,8-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-7-methyl-6-propyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-7-methyl-6-cyclopropylmethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-7-methyl-6-ethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-7-methyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-6-propyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-6-ethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
4-Trifluoromethyl-6-cyclopropylmethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;
6,7-Dihydro-8,8-dimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;
6,7-Dihydro-8,8,10-trimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;
(±)-6,7-Dihydro-6-ethyl-4-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;
(±)-7,8-Dihydro-8-ethyl-4-methyl-6H-pyrano[2,3-f]quinolin-2(1H)-one;
(±)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;

45026.00096.UTL1
PATENT

~~(-) 6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;~~
~~(+) 6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;~~
~~(±) 6,7-Dihydro-6-ethyl-3-fluoro-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;~~
~~(±) 6,7-Dihydro-6-ethyl-4-trifluoromethyl-1-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;~~
~~(±) 6,7-Dihydro-6-ethyl-3-fluoro-4-trifluoromethyl-1-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;~~
~~(±) 6,7-Dihydro-6-ethyl-2,4-bis(trifluoromethyl)-8H-pyrano[3,2-g]quinoline;~~
~~6,8,8-Trimethyl-4-trifluoromethyl-8H-pyrano[3,2-g]coumarin;~~
~~6-Ethyl-8,8-dimethyl-4-trifluoromethyl-8H-pyrano[3,2-g]coumarin;~~
~~(±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~7,8-Dihydro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;~~
~~6-(2,2,2-Trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;~~
~~8-Chloro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;~~
~~5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one; and~~
~~5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one.~~

41. (Currently amended) A compound according to claim 1, wherein said compound is selected from the group of:

~~8-Ethyl-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethyl-8-propylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;~~
~~(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;~~
~~(±)-6,6a,7,8,9a(cis)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;~~


45026.00096.UTL1
PATENT

- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-7,8-Dihydro-7,8-*cis*-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6*H*-pyrrolo[2,3-g]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano[g]pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- (±)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- 5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- 6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- 6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- 5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-f]quinolin-2(1*H*)-one;
- 5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1*H*)-one;

45026.00096.UTL1
PATENT


6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[i]pyrrolo[2,3-g]quinolin-2(1H)-one;
 7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;
 6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
 (+)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one; and
 (-)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
~~8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-5,7,7-trimethylpyrido[3,2-f]quinolin-2(1H)-one;~~
~~4-Trifluoromethyl-7-methyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;~~
~~6,7-Dihydro-8,8-dimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;~~
~~(-)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one; and~~
~~(+)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one.~~

42. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:




(I)

OR

45026.00096.UTL1
PATENT


(II)

OR




(III)

OR




(IV)

OR




(V)

OR

45026.00096.UTL1
PATENT


(VI)

OR



(VII)

OR



(VIII)

wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, NO_2 , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{13}$, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl and $\text{C}_1\text{-C}_8$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^2 is selected from the group of hydrogen, F, Cl, Br, I, CH_3 , CF_3 , CHF_2 , CH_2F , CF_2Cl , CN, $\text{CF}_2\text{OR}^{12}$, $\text{CH}_2\text{OR}^{12}$, OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{13}$, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkenyl and $\text{C}_2\text{-C}_8$ alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups may be optionally substituted;

R^3 through R^8 each independently is selected from the group of hydrogen, F, Cl, Br, I, OR^{12} , $\text{NR}^{12}\text{R}^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_2\text{-C}_8$ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups may be optionally substituted; or

R^3 and R^5 taken together form a bond; or

45026.00096.UTL1
PATENT

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally substituted;

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, CN, OR^{12} , $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}C(O)R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups may be optionally substituted;

R^{11} is selected from the group of hydrogen, F, Br, Cl, I, CN, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, OR^{14} , $NR^{14}R^{13}$, and SR^{14} , CH_2R^{14} , $C(O)R^{14}$, CO_2R^{14} , $C(O)NR^{14}R^{13}$, SOR^{14} and SO_2R^{14} , wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^{12} and R^{13} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted;

R^{14} is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups may be optionally substituted;

R^{15} and R^{16} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

W is O or S;

X is selected from the group of O, S and N(R^{14});

Y is selected from the group of O, S, N(R^{12}), and NO(R^{12}) and $CR^{12}R^{13}$;

Z is selected from the group of O, S and N(R^{12});

n is 0, 1 or 2;

m is 0[,] or 1;

and/or a pharmaceutically acceptable salts thereof.

45026.00096.UTL1
PATENT

43. (Original) A pharmaceutical composition according to claim 42, wherein the carrier is suitable for enteral, parenteral, suppository, or topical administration.

44. (Original) A pharmaceutical composition according to claim 42, wherein R^1 is selected from the group of hydrogen, F, Cl, Br, I, $C_1 - C_6$ alkyl, $C_1 - C_6$ haloalkyl and $C_1 - C_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

45. (Original) A pharmaceutical composition according to claim 44, wherein R^1 is selected from the group of hydrogen, F, Cl, $C_1 - C_4$ alkyl, $C_1 - C_4$ haloalkyl and $C_1 - C_4$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

46. (Original) A pharmaceutical composition according to claim 42, wherein R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , $C_1 - C_6$ alkyl, $C_1 - C_6$ haloalkyl and $C_1 - C_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

47. (Original) A pharmaceutical composition according to claim 46, wherein R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , $C_1 - C_4$ alkyl, $C_1 - C_4$ haloalkyl and $C_1 - C_4$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

48. (Original) A pharmaceutical composition according to claim 42, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, $C_1 - C_6$ alkyl, $C_1 - C_6$ haloalkyl and $C_1 - C_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

49. (Original) A pharmaceutical composition according to claim 48, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F and CH_3 .

50. (Currently amended) A pharmaceutical composition according to claim 42, wherein R^{11} is selected from the group of hydrogen, F, Br, Cl, CN, $C_1 - C_6$ alkyl, $C_1 - C_6$

45026.00096.UTL1
PATENT

haloalkyl, C₁-C₆ heteroalkyl, OR¹⁴, NR¹⁴R¹³, and SR¹⁴, ~~CH₂R₁₄, C(O)R₁₄, CO₂R₁₄, C(O)NR₁₄R₁₃, SOR₁₄ and SO₂R₁₄~~, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

51. (Currently amended) A pharmaceutical composition according to claim 50, wherein R¹¹ is selected from the group of hydrogen, F, Cl, OR¹⁴, SR¹⁴ and NR¹⁴R¹³; ~~CH₂R₁₄, C(O)R₁₄, CO₂R₁₄, C(O)NR₁₄R₁₃, SOR₁₄, SO₂R₁₄ and optionally substituted C₁-C₄ alkyl.~~

52. (Original) A pharmaceutical composition according to claim 42, wherein Y and W each independently is O or S.

53. (Original) A pharmaceutical composition according to claim 42, wherein Z is O or N(R¹²).

54. (Original) A pharmaceutical composition according to claim 42, wherein n is 0.

55. (Original) A pharmaceutical composition according to claim 42, wherein R¹² is selected from the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted.

56. (Original) A pharmaceutical composition according to claim 42, wherein X is O or N(R¹⁴).

57. (Original) A pharmaceutical composition according to claim 42, wherein R³ and R⁴ each independently is selected from the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R³ and R⁵ taken together form a bond; or

45026.00096.UTL1
PATENT

R^4 and R^6 taken together form a four to six membered carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

58. (Original) A pharmaceutical composition according to claim 42, wherein R^5 and R^7 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R^5 and R^7 taken together form a bond.

59. (Original) A pharmaceutical composition according to claim 42, wherein R^6 and R^8 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups may be optionally substituted; or

R^6 and R^8 taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

60. (Original) A pharmaceutical composition according to claim 42, wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; and

R^3 and R^4 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

61. (Original) A pharmaceutical composition according to claim 60, wherein:

R^5 through R^8 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

45026.00096.UTL1
PATENT

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

62. (Original) A pharmaceutical composition according to claim 61, wherein: R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R^{12} is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted; and

R^{14} is selected from the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

63. (Currently amended) A pharmaceutical composition according to claim 62, wherein:

W is O or S;

X is O or $N(R^{14})$;

Y is O or S[;]

Z is O or $N(R^{12})$; and

n is 0 or 1.

64. (Withdrawn) A method of treating an individual having a condition mediated by an androgen receptor comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims 1, 40 or 41.

65. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (I).

45026.00096.UTL1
PATENT

66. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (II).

67. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (III).

68. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (IV).

69. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (V).

70. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (VI).

71. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (VII).

72. (Withdrawn) A method according to claim 64, wherein said compound is represented by formula (VIII).

73. (Withdrawn) A method according to claim 64, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

74. (Withdrawn) A method according to claim 64, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

75. (Withdrawn) A method of modulating an androgen receptor in an individual comprising administering an androgen receptor modulating effective amount of a compound according to any one of claims 1, 40 or 41.

45026.00096.UTL1
PATENT

76. (Withdrawn) A method according to claim 64, wherein said individual has a condition mediated by an androgen receptor

77. (Withdrawn) A method according to claim 76, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

78. (Withdrawn) A method according to claim 76, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

79. (Withdrawn) A method according to claim 75, wherein said modulation is activation.

80. (Withdrawn) A method according to claim 76, wherein said individual has a condition mediated by an androgen receptor.

81. (Withdrawn) A method according to claim 80, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

82. (Withdrawn) A method according to claim 80, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

83. (Withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 100 nM.

84. (Withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 50 nM.

45026.00096.UTL1
PATENT

85. (Withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 20 nM.
86. (Withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 10 nM.
87. (Withdrawn) A method according to claim 75, wherein said modulation is inhibition.
88. (Withdrawn) A method according to claim 87, wherein said individual has a condition mediated by an androgen receptor.
89. (Withdrawn) A method according to claim 88, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.
90. (Withdrawn) A method according to claim 88, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.
91. (Withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 100 nM.
92. (Withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 50 nM.
93. (Withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 20 nM.
94. (Withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 10 nM.

45026.00096.UTL1
PATENT

95. (Withdrawn) A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1, 40 or 41.

96. (Withdrawn) A method of determining the presence of an androgen receptor (AR) in a cell or cell extract comprising: (a) labeling a compound according to any one of claims 1, 40 or 41; (b) contacting the cell or cell extract with said labeled compound; and (c) testing the contacted cell or cell extract to determine the presence of AR.

97. (Withdrawn) A method for purifying a sample containing an androgen receptor *in vitro*, comprising: (a) contacting said sample with a compound according to any one of claims 1, 40 or 41; (b) allowing said compound to bind to said androgen receptor to form a bound compound/receptor combination; and (c) isolating said bound compound/receptor combination.